Effects of the novel non-peptidyl low molecular weight radical scavenger IAC in different models of inflammation: A new perspective in anti-inflammatory therapy

Current Medicinal Chemistry

Volumn 17, Issue 32, 2010, Pages 3918-3924

  Corsi, L ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

IAC; Inflammation; Lipid peroxidation; Neuroprotection; PGE2; Radical scavenger; RNS; ROS

Indexed keywords

ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BIS (1 HYDROXY 2,2,6,7 TETRAMETHYL 4 PIPERIDINYL) DECANDIOATE; GLUTATHIONE; INTERCELLULAR ADHESION MOLECULE 1; NEUROPROTECTIVE AGENT; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN E2; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SCAVENGER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN ISCHEMIA; CELL PROTECTION; COLITIS; CYTOTOXICITY; DIABETES MELLITUS; DIABETIC PATIENT; DRUG EFFECT; DRUG EFFICACY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIPOTOXICITY; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET; STOMACH ULCER;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FREE RADICAL SCAVENGERS; FREE RADICALS; HUMANS; INFLAMMATION; MICE; PIPERIDINES; RATS;

EID: 78650643203     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710793205390     Document Type: Article

References (101)

1. Weiss, U. Inflammation. Nature, 2008, 45, 427.
2. Toriyabe, M.; Omote, K.; Kawamata, T.; Namiki, A. Contribution of interaction between nitric oxide and cyclooxygenases to the production of prostaglandins in carrageenan-induced inflammation. Anesthesiology, 2004, 10, 983-890.
3. Loram, L. C.; Fuller, A.; Cartmell, T.; Mitchell, B.; Mitchell, D. Behavioural, histological and cytokine responses during hyperalgesia induced by carrageenan injection in the rat tail. Physiol. Behav., 2007, 92, 873-880.
4. Stassen, M.; Hültner, L.; Schmitt, E. Classical and alternative pathways of mast cell activation. Crit. Rev. Immunol,. 2002, 22, 115-140.
5. Oka, Y.; Ibuki, T.; Matsumura, K.; Namba, M.; Yamazaki, Y.; Poole, S.; Tanaka, Y.; Kobayashi, S. Interleukin-6 is a candidate molecule that transmits inflammatory information to the CNS. Neuroscience, 2007, 145, 530-538.
6. Emerit, J.; Edeas, M.; Bricaire, F. Neurodegenerative diseases and oxidative stress. Biomed. Pharmacother., 2004, 58, 39-46.
7. Lamb, R. E.; Goldstein, B. J. Modulating an oxidative-inflammatory cascade: potential new treatment strategy for improving glucose metabolism, insulin resistance, and vascular function. Int. J. Clin. Pract., 2010, 62, 1087-1095.
8. Hotamisligil, G. S. Inflammation and metabolic disorders. Nature, 2006, 444, 860-867.
9. Feld, J. J.; Hoofnagle, J. H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature, 2005, 436, 967-972.
10. Hanauer, S. B.; Sandborn, W. J.; Rutgeerts, P.; Fedorak, R. N.; Lukas, M.; MacIntosh, D.; Panaccione, R.; Wolf, D.; Pollack, P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology, 2006, 130, 323-333.
11. Rutgeerts, P.; Sandborn, W. J.; Feagan, B. G.; Reinisch, W.; Olson, A.; Johanns, J.; Travers, S.; Rachmilewitz, D.; Hanauer, S. B.; Lichtenstein, G. R.; de Villiers, W. J.; Present, D.; Sands, B. E.; Colombel, J. F. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med., 2005, 353, 2462-2476. (Pubitemid 41770166)
12. Clancy, R. M.; Amin, A. R.; Abramson, S. B. The role of nitric oxide in inflammation and immunity. Arthritis Rheum., 1998, 41, 1141-1151.
13. Ohshima, H.; Bartsch, H. Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat. Res., 1994, 3005, 253-264.
14. Balkwill, F.; Mantovani, A. Inflammation and cancer: back to Virchow? Lancet, 2001, 357, 539-545.
15. Coussens, L. M.; Werb, Z. Inflammation and cancer. Nature, 2002, 420, 860-867.
16. Hussain, S. P.; Hofseth, L. J.; Harris, C. C. Radical causes of cancer. Nat. Rev. Cancer, 2003, 3, 276-285.
17. Clancy, R. M.; Abramson, S. B.; Nitric oxide: a novel mediator of inflammation. Proc. Soc. Exp. Biol. Med., 1995, 210, 93-101.
18. Ahmad, R.; Rasheed, Z.; Ahsan, H. Biochemical and cellular toxicology of peroxynitrite: implications in cell death and autoimmune phenomenon. Immunopharmacol. Immunotoxicol., 2009, 31, 388-96.
19. Shibata, N.; Kobayashi, M. The role for oxidative stress in neurodegenerative diseases. Brain Nerve, 2008, 157, 60-70.
20. Grisham, M. B. Oxidants and free radicals in inflammatory bowel disease. Lancet, 1994, 344, 859-861.
21. Stocker, R.; Keaney, J. F. Jr. Role of oxidative modifications in atherosclerosis. Physiol. Rev., 2004, 84, 1381-1478.
22. Sun, J.; Druhan, L. J.; Zweier, J. L. Reactive oxygen and nitrogen species regulate inducible nitric oxide synthase function shifting the balance of nitric oxide and superoxide production. Arch. Biochem. Biophys., 2010, 494, 130-137.
23. Griffin, M. R.; Piper, J. M.; Daugherty, J. R.; Snowden, M.; Ray, W. A. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann. Intern. Med., 1991, 114, 257-263.
24. Whittle, B. J. Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat. Gastroenterology, 1981, 80, 94-98.
25. Wallace, J. L.; McKnight, W.; Reuter, B. K.; Vergnolle, N. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology, 2000, 119, 706-714.
26. Tanaka, A.; Hase, S.; Miyazawa, T.; Ohno, R.; Takeuchi, K. Role of cyclooxygenase (COX)-1 and COX-2 inhibition in nonsteroidal anti-inflammatory drug-induced intestinal damage in rats: relation to various pathogenic events. J. Pharmacol. Exp. Ther., 2002, 303, 1248-1254.
27. Suzuki, K.; Araki, H.; Komoike, Y.; Takeuchi, K. Permissive role of neutrophils in pathogenesis of indomethacin-induced gastric lesions in rats. Med. Sci. Monit., 2000, 6, 908-914.
28. Slomiany, B. L.; Piotrowski, J.; Slomiany, A. Induction of tumor necrosis factor-alpha and apoptosis in gastric mucosal injury by indomethacin: effect of omeprazole and ebrotidine. Scand. J. Gastroenterol. 1997, 32, 638-642.
29. Valgimigli, L.; Pedulli, G. F.; Paolini, M. Measurement of oxidative stress by EPR radical-probe technique. Free Radic. Biol. Med., 2001, 31, 708-716.
30. Vlgimigli, L.; Valgimigli, M.; Gaiani, S.; Pedulli, G. F.; Bolondi L. Measurement of oxidative stress in human liver by EPR spin-probe technique. Free Rad. Res., 2000, 33, 167-178.
31. Behrens, R. A., Seltzer, A., Inventors. CIBA Geigy Corporation, USA, assignee, 1987, US Pat. No. 4, 691, 015.
32. Crippen, G. M. Why energy embedding works. J. Phys. Chem., 1987, 91, 6341-6343.
33. Fang, J.; Seki, T.; Maeda, H. Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv. Drug Deliv. Rev., 2009, 61, 290-302.
34. Demple, B.; Harrison, L. Repair of oxidative damage to DNA: enzymology and biology. Annu. Rev. Biochem., 1994, 63, 915-948.
35. Kunsch, C.; Medford, R. M. Oxidative stress as a regulator of gene expression in the vasculature. Circ. Res., 1999, 85, 753-766.
36. Creager, M. A.; Luscher, T. F.; Cosentino, F.; Beckman, J. A. Diabetes and vascular disease: pathophysiology, clinical consequences, and medicaltherapy: part I. Circulation, 2003, 108, 1527-1532. (Pubitemid 37176462)
37. Tuncman, G.; Hirosumi, J.; Solinas, G.; Chang, L.; Karin, M.; Hotamisligil, G. S. Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. PNAS, 2006, 103, 10741-10746.
38. Tumur, Z.; Shimizu, H.; Enomoto, A.; Miyazaki, H.; Niwa, T. Indoxyl sulfate upregulates expression of ICAM-1 and MCP-1 by oxidative stress-induced NF-kB activation. Am. J. Nephrol., 2010, 31, 435-441.
39. Sarada, S.; Himadri, P.; Mishra, C.; Geetali, P.; Ram, M. S.; Ilavazhagan, G. Role of oxidative stress and NFkB in hypoxiainduced pulmonary edema. Exp. Biol. Med., 2008, 233, 1088-1098.
40. Lipton, S. A.; Choi, Y. B.; Pan, Z. H.; Lei, S. Z.; Chen, H. S.; Sucher, N. J.; Loscalzo, J.; Singel, D. J.; Stamler, J. S. A redox based mechanism for the neuroprotective and neurodestructive effects of NO and related nitroso-compounds. Nature, 1993, 364, 626-632.
41. Dopp, J. M.; Sarafian, T. A.; Spinella, F. M.; Kahn, M. A.; Shau, H.; de Vellis, J. Expression of the p75 TNF receptor is linked to TNF-induced NFkappaB translocation and oxyradical neutralization in glial cells. Neurochem. Res., 2002, 27, 1535-42.
42. Lander, H. M.; Sehajpal, P.; Levine, D. M.; Novogrodsky, A. Activation of human peripheral blood mononuclear cells by nitric oxide-generating compounds. J. Immunol., 1993, 150, 1509-1516.
43. Amini-Shirazi, N.; Hoseini, A.; Ranjbar, A.; Mohammadirad, A.; Khoshakhlagh, P.; Yasa, N.; Abdollahi, M.; Inhibition of tumor necrosis factor and nitrosative/oxidative stresses by Ziziphora clinopoides (Kahlioti); a molecular mechanism of protection against dextran sodium sulfate-induced colitis in mice. Toxicol. Mech. Methods., 2009, 19, 183-189.
44. Sehara, Y.; Hayashi, T.; Deguchi, K.; Zhang, H.; Tsuchiya, A.; Yamashita, T.; Lukic, V.; Nagai, M.; Kamiya, T.; Abe, K. Decreased focal inflammatory response by G-CSF may improve stroke outcome after transient middle cerebral artery occlusion in rats. J. Neurosci. Res. 2007, 85, 2167-2174.
45. Laroux, F. S.; Pavlick, K. P.; Hines, I. N.; Kawachi, S.; Harada, H.; Bharwani, S.; Hoffman, J. M.; Grisham, M. B. Role of nitric oxide in inflammation. Acta Physiol. Scand., 2001, 173, 113-118.
46. Park, S. K.; Lin, H. L.; Murphy, S. Nitric oxide regulates nitric oxide synthase-2 gene expression by inhibiting NF-kappaB binding to DNA. Biochem. J., 1997, 322, 609-613.
47. Vasquez-Vivar, J.; Kalyanaraman, B.; Martasek, P.; Hogg, N.; Masters, B. S.; Karoui. H.; Tordo, P.; Pritchard, K. A. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc. Natl. Acad. Sci. U. S. A., 1998, 95, 9220-9225. (Pubitemid 28506212)
48. Laursen, J.; Somers, M.; Kurz, S.; McCann, L.; Warnholtz, A.; Freeman, B. A.; Tarpey, M.; Fukai, T.; Harrison, D. G. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation, 2001, 103, 1282-1288.
49. Crama-Bohbouth, G. E.; Arndt, J. W.; Pena, A. S.; Verspaget, H. W.; Tjon, A. T. R.; Weterman, I. T.; Pauwels, E. K.; Lamers, C. B. Value of indium-111 granulocyte scintigraphy in the assessment of Crohn's disease of the small intestine: prospective investigation. Digestion, 1988, 40, 227-236.
50. Verspaget, H. W., Pena, A. S., Weterman, I. T., Lamers, C. B. Diminished neutrophil function in Crohn's disease and ulcerative colitis identified by decreased oxidative metabolism and low superoxide dismutase content. Gut, 1988, 29, 223-228.
51. Cuzzocrea, S.; Zingarelli, B.; Hake, P.; Salzman, A. L.; Szabo, C. Antiinflammatory effects of mercaptoethylguanidine, a combined inhibitor of nitric oxide synthase and peroxynitrite scavenger, in carrageenan-induced models of inflammation. Free Radic. Biol. Med., 1998, 24, 450-459.
52. Aiko, S.; Grisham, M. B. Spontaneous intestinal inflammation and nitric oxide metabolism in HLA-B27 transgenic rats. Gastroenterol., 1995, 109, 142-150.
53. Mourelle, M.; Vilaseca, J.; Guarner, F.; Salas, A.; Malagelada, J. R. Toxic dilatation of colon in a rat model of colitis is linked to an inducible form of nitric oxide synthase. Am. J. Physiol., 1996, 270, G425-G430.
54. Ikeda, I.; Kasajima, T.; Ishiyama, S.; Shimojo, T.; Takeo, Y.; Nishikawa, T.; Kameoka, S.; Hiroe, M.; Mitsunaga, A. Distribution of inducible nitric oxide synthase in ulcerative colitis. Am. J. Gastroenterol., 1997, 92, 1339-1341.
55. Middleton, S. J.; Shorthouse, M.; Hunter, J. O. Increased nitric oxide synthesis in ulcerative colitis. Lancet, 1993, 20, 465-466.
56. Vasina, V.; Broccoli, M.; Ursino, M. G.; Bellot, S. F.; Soleti, A.; Paolini, M.; De Ponti, F. Effects of the non-peptidyl low molecular weight radical scavenger IAC in DNBS-induced colitis in rats. Eur. J. Pharmacol., 2009, 614, 137-145.
57. Zavatti, M.; Corsi, L.; Zanoli, P.; Baraldi, M. Anti-ulcer activity of IAC, a novel free-radical scavenger, in rats. J. Pharm. Pharmacol., 2009, 61, 395-397.
58. Lupi, R.; Del Guerra, S.; Mancarella, R.; Novelli, M.; Valgimigli, L.; Pedulli, G. F.; Paolini, M.; Soleti, A.; Filipponi, F.; Mosca, F.; Boggi, U.; Del Prato, S.; Masiello, P.; Marchetti, P. Insulin secretion defects of human type 2 diabetic islets are corrected in vitro by a new reactive oxygen species scavenger. Diabetes Metab., 2007, 33, 340-345.
59. Maechler, P.; De Andrade, P. B. Mitochondrial damages and the regulation of insulin secretion. Biochem. Soc. Trans., 2006, 34, 824-827.
60. Robertson, R. P. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J. Biol. Chem., 2004, 279, 42351-42454.
61. Robertson, R. P.; Harmon, J. S. Diabetes, glucose toxicity, and oxidative stress: A case of double jeopardy for the pancreatic islet beta cell. Free Radic. Biol. Med., 2006, 41, 177-184.
62. Warram, J. H.; Martin, B. C.; Krolewski, A. S.; Soeldner, J. S.; Kahn, C. R. Slow glucose removal rate and hyperinsulinemia precede the development of type-II diabetes in the offspring of diabetic parents. Ann. Intern. Med., 1990, 113, 909-15.
63. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes, 2005, 54, 1-7.
64. Laybutt, D. R.; Kaneto, H., Hasenkamp, W.; Grey, S.; Jonas, J. C.; Sgroi, D. C.; Groff, A.; Ferran, C.; Bonner-Weir, S.; Sharma, A.; Weir, G. C. Increased expression of antioxidant and antiapoptotic genes in islets that may contribute to beta-cell survival during chronic hyperglycemia. Diabetes, 2002, 51, 413-23.
65. Goldstein BJ, Mahadev K, Wu X. Redox paradox: insulin action is facilitated by insulin-stimulated reactive oxygen species with multiple potential signaling targets. Diabetes, 2005, 54, 311-21.
66. Goligorsky MS. Endothelial cell dysfunction: can't live with it, howto live without it. Am. J. Physiol. Renal. Physiol., 2005, 288, 871-80.
67. Seghrouchni, I.; Drai, J.; Bannier, E.; et al. Oxidative stress parameters in type I, type II and insulin-treated type 2 diabetes mellitus; insulin treatment efficiency. Clin. Chim. Acta, 2002, 321, 89-96.
68. Novelli, M.; D'Aleo, V.; Lupi, R.; Paolini, M.; Soleti, A.; Marchetti, P.; Masiello, P. Pancreas, Reduction of oxidative stress by a new low-molecular-weight antioxidant improves metabolic alterations in a nonobese mouse diabetes model. 2007, 35, e10-7.
69. Mancarella, R.; Del Guerra, S.; Masini, M.; Bugliani, M.; Valgimigli, L.; Pedulli, G. F.; Paolini, M., Canistro, D., Armando, A., Soleti, A., Filipponi, F., Mosca, F., Boggi, U., Del Prato, S.; Marchetti, P.; Lupi, R. Beneficial effect of the nonpeptidyl low molecular weight radical scavenger IAC on cultured human islet function. Cell Transplant., 2008, 17, 1271-1276.
70. Benhamou, P. Y.; Moriscot, C.; Badet, L.; Halimi, S. Strategies for graft immunomodulation in islet transplantation. Diabetes Metab., 1998, 24, 215-224.
71. Bottino, R.; Balamurugan, A. N.; Tse, H.; Thirunavukkarasu, C.; Ge, X.; Profozich, J.; Milton, M.; Ziegenfuss, A.; Trucco, M.; Piganelli, J. D. Response of human islets to isolation stress and the effect of antioxidant treatment. Diabetes, 2004, 53, 2559-2568.
72. D'Aleo, V.; Del Guerra, S.; Martano, M.; Bonamassa, B.; Canistro, D.; Soleti, A.; Valgimigli, L.; Paolini, M.; Filipponi, F.; Boggi, U.; Del Prato, S.; Lupi, R. The non-peptidyl low molecular weight radical scavenger IAC protects human pancreatic islets from lipotoxicity. Mol. Cell. Endocrinol., 2009, 309, 63-66.
73. Lo, E. H.; Dalkara, T.; Moskowitz, M. A. Mechanisms, challenges and opportunities in stroke. Nat. Rev. Neurosci., 2003, 4, 399-415.
74. Donnan, G. A.; Fisher, M.; Macleod, M.; Davis, S. M. Stroke. Lancet, 2008, 371, 1612-1623.
75. Ying, W. NAD+ and NADH in brain functions, brain diseases and brain aging. Front. Biosci., 2007, 12, 1863-1888.
76. Chan, P. H. Role of oxidants in ischemic brain damage. Stroke, 1996, 27, 1124-1129.
77. Lee, J. M.; Zipfel, G. J.; Choi, D. W. The changing landscape of ischaemic brain injury mechanisms. Nature, 1999, 399, A7-14.
78. Kristian, T.; Siesjo, B. K. Calcium in ischemic cell death. Stroke, 1998, 29, 705-718.
79. Kriz, J. Inflammation in ischemic brain injury: timing is important. Crit. Rev. Neurobiol., 2006, 18, 145-157.
80. Tuttolomondo, A.; Di Raimondo, D.; di Sciacca, R.; Pinto, A.; Licata, G. Inflammatory cytokines in acute ischemic stroke. Curr. Pharm. Des., 2008, 14, 3574-3589.
81. Wang, Q.; Tang, X. N.; Yenari, M. A. The inflammatory response in stroke. J. Neuroimmunol., 2007, 184, 53-68.
82. Yilmaz, G.; Granger, D. N. Cell adhesion molecules and ischemic stroke. Neurol. Res., 2008, 30, 783-793.
83. Stoll, G.; Jander, S.; Schroeter, M. Inflammation and glial responses in ischemic brain lesions. Prog. Neurobiol., 1998, 56, 149-171.
84. Muscoli, C.; Mollace, V.; Wheatley, J.; Masini, E.; Ndengele, M.; Wang, Z. Q.; Salvemini, D. Superoxide-mediated nitration of spinal manganese superoxide dismutase: a novel pathway in N-methyl-D-aspartate-mediated hyperalgesia. Pain, 2004, 111, 96-103.
85. Ajith, T. A.; Riji, T.; Anu, V. In vitro anti-oxidant and DNA protective effects of the novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin. Clin. Exp. Pharmacol. Physiol., 2008, 35, 625-629.
86. Cuzzocrea, S.; Riley, D. P.; Caputi, A. P.; Salvemini, D. Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol. Rev., 2001, 53, 135-159.
87. Shih, A. Y.; Li, P.; Murphy, T. H. A small-molecule-inducible Nrf2-mediated antioxidant response provides effective prophylaxis against cerebral ischemia in vivo. J. Neurosci., 2005, 25, 10321-10335.
88. Sena, E.; Wheble, P.; Sandercock, P.; Macleod, M. Systematic review and meta-analysis of the efficacy of tirilazad in experimental stroke. Stroke, 2007, 38, 388-394.
89. Kuroda, S.; Tsuchidate, R.; Smith, M. L.; Maples, K. R.; Siesjö, B. K. Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. J. Cereb. Blood Flow Metab., 1999, 19, 778-787.
90. van der Worp, H. B.; Kappelle, L. J.; Algra, A.; Bär, P. R.; Orgogozo, J. M.; Ringelstein, E. B.; Bath P. M.; van Gijn, J. The effect of tirilazad mesylate on infarct volume of patients with acute ischemic stroke. Neurology, 2002, 58, 133-135.
91. Sydserff, S. G., Borelli, A. R., Green, A. R., Cross, A. J. Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window. Br. J. Pharmacol., 2002, 135, 103-112.
92. Salom, J. B.; Pérez-Asensio, F. J.; Burguete, M. C.; Marín, N.; Pitarch, C.; Torregrosa, G.; Romero F. J.; Alborch, E. Single-dose ebselen does not afford sustained neuroprotection to rats subjected to severe focal cerebral ischemia. Eur. J. Pharmacol., 2004, 495, 55-62.
93. Green, A. R.; Ashwood, T. Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers. Curr. Drug Targets CNS Neurol. Disord., 2005, 4, 109-118.
94. Doggrell, S. A. Nitrone spin on cerebral ischemia. Curr. Opin. Investig. Drugs, 2006, 7, 20-24.
95. Koziol, J. A.; Feng, A. C. On the analysis and interpretation of outcome measures in stroke clinical trials: lessons from the SAINT I study of NXY-059 for acute ischemic stroke. Stroke, 2006, 37, 2644-2647.
96. Hill, M. D. Stroke: the dashed hopes of neuroprotection. Lancet Neurol., 2007, 6, 2-3.
97. Canistro, D.; Affatato, A. A.; Soleti, A.; Mollace, V.; Muscoli, C.; Sculco, F.; Sacco, I.; Visalli, V.; Bonamassa, B.; Martano, M.; Iannone, M.; Sapone, A.; Paolini, M. The novel radical scavenger IAC is effective in preventing and protecting against post-ischemic brain damage in Mongolian gerbils. J. Neurol. Sci., 2010, 290, 90-95.
98. Nurmi, A.; Miettinen, T. K.; Puoliväli, J.; Pussinen, R.; Soleti, A.; Bagate, K.; Riccardino, F.; Grundy, R. I.; Yrjänheikki, J.; Canistro, D.; Paolini, M. Neuroprotective properties of the non-peptidyl radical scavenger IAC in rats following transient focal cerebral ischemia. Brain Res., 2008, 1207, 174.
99. Yu, H.; Pan, C.; Zhao, S.; Wang, Z.; Zhang, H.; Wu, W. Resveratrol inhibits tumor necrosis factor-alpha-mediated matrix metalloproteinase-9 expression and invasion of human hepatocellular carcinoma cells. Biomed. Pharmacother., 2008, 62, 366-372.
100. Banerjee, S.; Bueso-Ramos, C.; Aggarwal, B. B. Suppression of 7, 12-dimethylbenz (a) anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factorkappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res., 2002, 62, 4945-4954.
101. Kundu, J. K.; Shin, Y. K.; Kim, S. H.; Surh, Y. J. Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-kappaB in mouse skin by blocking IkappaB kinase activity. Carcinogenesis 2006, 27, 1465-1474.